Dr. William Grady
Add to your Care-Team
Dr. William Grady
Dr. William Grady
I specialize in
Internal Medicine - Gastroenterology
I have been in practice
My answers and insights have
Helped 20 people
Here are kind words from others
This Thanksgiving, I wanted to share my appreciation for all that you do! Thank you, doctor! :)
I am located at
1100 Fairview Ave N D4-100
Seattle , WA 98109
825 Eastlake Ave. E
Seattle , WA 98109
1959 NE Pacific St
Seattle , WA 98195
I was educated and trained at
Medical / Graduate School
University of Michigan Medical School
Dr. William Grady M
I've won the following awards
Top Doctor, Seattle Metropolitan Magazine
Presidential Early Career Award for Scientists and Engineers, Department of Veterans Affairs
Damon Runyon-Lilly Clinical Investigator Award, Damon Runyon Cancer Research Foundation
Mallinckrodt Scholar Award, 42nd Scholar, Edward Mallinckrodt Jr. Foundation
John Walsh Memorial GIDH Award in Basic Research, John Walsh Memorial
DNA Methylation Profiling across the Spectrum of HPV-Associated Anal Squamous Neoplasia.
PLoS ONE., 7(11):e50533 (2012)
DNA methylation and gene expression profiling of ewing sarcoma primary tumors reveal genes that are potential targets of epigenetic inactivation.
Sarcoma., 2012:498472 (2012)
Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer.
Therap Adv Gastroenterol., Sep;5(5):319-37 (2012)
RET is a potential tumor suppressor gene in colorectal cancer.
Oncogene., Jul (2012)
Colorectal endoscopy, advanced adenomas, and sessile serrated polyps: implications for proximal colon cancer.
Am. J. Gastroenterol., Aug;107(8):1213-9 (2012)
Fbw7 and p53 cooperatively suppress advanced and chromosomally unstable intestinal cancer.
Mol. Cell. Biol., Jun;32(11):2160-7 (2012)
Epigenetic biomarkers in esophageal cancer.
Cancer Lett., Mar (2012)
Variation in age at cancer diagnosis in familial versus nonfamilial Barrett's esophagus.
Cancer Epidemiol. Biomarkers Prev., Feb;21(2):376-83 (2012)
Aberrantly methylated PKP1 in the progression of Barrett's esophagus to esophageal adenocarcinoma.
Genes Chromosomes Cancer., Apr;51(4):384-93 (2012)
DNA methylation profiling in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses.
Epigenetics., Dec;6(12):1403-12 (2011)
Epigenetics and colorectal cancer.
Nat Rev Gastroenterol Hepatol., Dec;8(12):686-700 (2011)
Association of insulin and insulin-like growth factors with Barrett's oesophagus.
Gut., May;61(5):665-72 (2012)
Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss.
Hepatology., Jan;55(1):121-31 (2012)
Quality assessment and correlation of microsatellite instability and immunohistochemical markers among population- and clinic-based colorectal tumors results from the Colon Cancer Family Registry.
J Mol Diagn., May;13(3):271-81 (2011)
Epigenomic analysis of aberrantly methylated genes in colorectal cancer identifies genes commonly affected by epigenetic alterations.
Ann. Surg. Oncol., Aug;18(8):2338-47 (2011)
Linking epidemiology to epigenomics--where are we today?
Cancer Prev Res (Phila)., Dec;3(12):1505-8 (2010)
Colorectal cancer molecular biology moves into clinical practice.
Gut., Jan;60(1):116-29 (2011)
Use of folic acid-containing supplements after a diagnosis of colorectal cancer in the Colon Cancer Family Registry.
Cancer Epidemiol. Biomarkers Prev., Aug;19(8):2023-34 (2010)
The next thing in prognostic molecular markers: microRNA signatures of cancer.
Gut., Jun;59(6):706-8 (2010)
Insights into the role of DNA methylation in disease through the use of mouse models.
Dis Model Mech., 3(5-6):290-7 (2010 May-Jun)
A segregation analysis of Barrett's esophagus and associated adenocarcinomas.
Cancer Epidemiol. Biomarkers Prev., Mar;19(3):666-74 (2010)
TGF-beta inactivation and TGF-alpha overexpression cooperate in an in vivo mouse model to induce hepatocellular carcinoma that recapitulates molecular features of human liver cancer.
Int. J. Cancer., Sep;127(5):1060-71 (2010)
Aberrant DNA methylation occurs in colon neoplasms arising in the azoxymethane colon cancer model.
Mol. Carcinog., Jan;49(1):94-103 (2010)
Comparative analysis of PCR-based biomarker assay methods for colorectal polyp detection from fecal DNA.
Clin. Chem., Aug;55(8):1559-63 (2009)
Assessment of familiality, obesity, and other risk factors for early age of cancer diagnosis in adenocarcinomas of the esophagus and gastroesophageal junction.
Am. J. Gastroenterol., Aug;104(8):1913-21 (2009)
TGF-beta receptor levels regulate the specificity of signaling pathway activation and biological effects of TGF-beta.
Biochim. Biophys. Acta., Jul;1793(7):1165-73 (2009)
TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway.
Gastroenterology., May;136(5):1680-8.e7 (2009)
Genomic and epigenetic instability in colorectal cancer pathogenesis.
Gastroenterology., Oct;135(4):1079-99 (2008)
TGF-beta has paradoxical and context dependent effects on proliferation and anoikis in human colorectal cancer cell lines.
Growth Factors., Oct;26(5):254-62 (2008)
The aberrant methylation of TSP1 suppresses TGF-beta1 activation in colorectal cancer.
Int. J. Cancer., Jul;123(1):14-21 (2008)
Making the case for DCC and UNC5C as tumor-suppressor genes in the colon.
Gastroenterology., Dec;133(6):2045-9 (2007)
Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor beta resistant cells.
Genes Chromosomes Cancer., Feb;47(2):95-106 (2008)
CIMP and colon cancer gets more complicated.
Gut., Nov;56(11):1498-500 (2007)
Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci.
Cancer Res., Jul;67(14):6882-8 (2007)
Consortium approach to identifying genes for Barrett's esophagus and esophageal adenocarcinoma.
Transl Res., Jul;150(1):3-17 (2007)
Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas.
Cancer Cell., Mar;11(3):229-43 (2007)
DNA alkylation and DNA methylation: cooperating mechanisms driving the formation of colorectal adenomas and adenocarcinomas?
Gut., Mar;56(3):318-20 (2007)
Evidence for the role of aberrant DNA methylation in the pathogenesis of Lynch syndrome adenomas.
Int. J. Cancer., May;120(9):1922-9 (2007)
Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation.
Cancer Res., Oct;66(20):9837-44 (2006)
Genomic instability and colorectal cancer.
Curr. Opin. Gastroenterol., Jan;16(1):62-7 (2000)
Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction.
Cancer Epidemiol. Biomarkers Prev., Sep;15(9):1668-73 (2006)
Promoter methylation status of the MGMT, hMLH1, and CDKN2A/p16 genes in non-neoplastic mucosa of patients with and without colorectal adenomas.
Oncol. Rep., Aug;16(2):429-35 (2006)
CpG island methylation of genes accumulates during the adenoma progression step of the multistep pathogenesis of colorectal cancer.
Genes Chromosomes Cancer., Aug;45(8):781-9 (2006)
Do adverse histopathologic findings in colorectal cancer patients explain disparate outcomes?
J Natl Med Assoc., Mar;98(3):348-51 (2006)
Proliferation and Cdk4 expression in microsatellite unstable colon cancers with TGFBR2 mutations.
Int. J. Cancer., Feb;118(3):600-8 (2006)
Transforming growth factor-beta, Smads, and cancer.
Clin. Cancer Res., May;11(9):3151-4 (2005)
Keratin 19 gene drives Cre recombinase expression throughout the early postimplantation mouse embryo.
Genesis., May;42(1):23-7 (2005)
Ionizing radiation and rectal cancer: victims of our own success.
Gastroenterology., Apr;128(4):1114-7 (2005)
Inactivation of TGF-beta signaling in hepatocytes results in an increased proliferative response after partial hepatectomy.
Oncogene., Apr;24(18):3028-41 (2005)
Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps.
Clin. Cancer Res., Feb;11(3):1203-9 (2005)
Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer.
Cancer Res., Jul;64(14):4687-92 (2004)
Surveillance and Treatment of Periampullary and Duodenal Adenomas in Familial Adenomatous Polyposis.
Curr Treat Options Gastroenterol., Apr;7(2):79-89 (2004)
Genomic instability and colon cancer.
Cancer Metastasis Rev., 23(1-2):11-27 (2004 Jan-Jun)
Diagnosis and management of hereditary non-polyposis colon cancer.
Gastrointest. Endosc., Sep;58(3):390-408 (2003)
GISTs: the revolution continues.
Gastroenterology., Sep;125(3):967-9 (2003)
Genetic testing for high-risk colon cancer patients.
Gastroenterology., May;124(6):1574-94 (2003)
Hereditary colon cancer genes.
Methods Mol. Biol., 222:59-83 (2003)
Genetic and epigenetic alterations in colon cancer.
Annu Rev Genomics Hum Genet., 3:101-28 (2002)
Hereditary diffuse gastric cancer: more answers or more questions?
Gastroenterology., Mar;122(3):830-1; discussion 831-2 (2002)
Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer.
Cancer Res., Feb;61(3):900-2 (2001)
Mutation Detection inTGF-Î² Receptors.
Methods Mol. Med., 50:99-111 (2001)
Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer.
Nat. Genet., Sep;26(1):16-7 (2000)
p27 cell-cycle inhibitor is inversely correlated with lymph node metastases in right-sided colon cancer.
J. Clin. Lab. Anal., 13(6):291-5 (1999)
Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers.
Cancer Res., Jan;59(2):320-4 (1999)
Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas.
Cancer Res., Jul;58(14):3101-4 (1998)
Mini-microabscess syndrome in liver transplant recipients.
Hepatology., Jul;26(1):192-7 (1997)
Dr. William Grady M